Risk factors for rituximab-induced interstitial lung diseases in patients with malignant lymphoma

摘要

Rituximab, a chimeric human-mouse immunoglobulin Gl monoclonal antibody with a high affinity for CD20 surface antigen expressed by normal human pre-B and B lymphocytes, has been approved for low-grade non-Hodgkin's lymphoma expressing CD20, chronic lymphocytic leukemia and diffuse large B cell lymphoma [1]. Currently, it is regarded as part of the standard therapy for treatment of CD20+ non-Hodgkin's lymphoma [2]. Although the incidence of rituximab-induced interstitial lung disease (ILD) was estimated to be very rare by the manufacturer (< 0.03%) [3], it has been reported more frequently (8.4-11%) in a few studies [4, 5]. A systematic review has described the detailed clinical characteristics of rituximab-induced lung diseases [1]. However, data regarding the risk factors for rituximab-induced ILD in patients with malignant lymphoma are lacking.